Analysts Anticipate Caladrius Biosciences Inc (NASDAQ:CLBS) to Announce -$0.44 Earnings Per Share

Share on StockTwits

Equities analysts expect that Caladrius Biosciences Inc (NASDAQ:CLBS) will report earnings per share of ($0.44) for the current quarter, Zacks reports. Zero analysts have made estimates for Caladrius Biosciences’ earnings. The highest EPS estimate is ($0.43) and the lowest is ($0.44). Caladrius Biosciences posted earnings of ($0.42) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 4.8%. The firm is expected to report its next quarterly earnings results on Thursday, August 8th.

According to Zacks, analysts expect that Caladrius Biosciences will report full year earnings of ($1.66) per share for the current financial year, with EPS estimates ranging from ($1.88) to ($1.34). For the next year, analysts anticipate that the firm will report earnings of ($1.11) per share, with EPS estimates ranging from ($1.90) to ($0.70). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that cover Caladrius Biosciences.

Caladrius Biosciences (NASDAQ:CLBS) last issued its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.05).

Several research analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of Caladrius Biosciences from a “sell” rating to a “hold” rating in a research report on Tuesday, June 11th. WBB Securities assumed coverage on shares of Caladrius Biosciences in a research report on Tuesday, May 14th. They set a “speculative buy” rating and a $6.75 price target for the company. Chardan Capital reaffirmed a “buy” rating and set a $6.00 price objective on shares of Caladrius Biosciences in a research note on Sunday, May 12th. ValuEngine cut shares of Caladrius Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st. Finally, Dawson James reaffirmed a “buy” rating on shares of Caladrius Biosciences in a research note on Wednesday, February 27th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $9.25.

An institutional investor recently bought a new position in Caladrius Biosciences stock. Wesbanco Bank Inc. acquired a new stake in Caladrius Biosciences Inc (NASDAQ:CLBS) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $36,000. Wesbanco Bank Inc. owned approximately 0.10% of Caladrius Biosciences at the end of the most recent quarter. Institutional investors and hedge funds own 7.59% of the company’s stock.

Shares of CLBS traded down $0.06 during mid-day trading on Thursday, hitting $2.25. 59,105 shares of the company were exchanged, compared to its average volume of 32,622. Caladrius Biosciences has a 1-year low of $2.18 and a 1-year high of $6.84. The firm’s 50 day simple moving average is $2.86.

Caladrius Biosciences Company Profile

Caladrius Biosciences, Inc is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.

Featured Story: Should You Consider an Index Fund?

Get a free copy of the Zacks research report on Caladrius Biosciences (CLBS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with's FREE daily email newsletter.